Amalgamated Bank Buys 42,813 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Amalgamated Bank lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 724.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 48,721 shares of the biotechnology company’s stock after acquiring an additional 42,813 shares during the quarter. Amalgamated Bank owned approximately 0.05% of Sarepta Therapeutics worth $7,698,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $26,000. Dimensional Fund Advisors LP raised its holdings in Sarepta Therapeutics by 10.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock valued at $21,621,000 after acquiring an additional 20,923 shares during the period. Principal Financial Group Inc. raised its holdings in Sarepta Therapeutics by 125.3% during the fourth quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock valued at $4,777,000 after acquiring an additional 27,549 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Sarepta Therapeutics by 65.2% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,108 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,227 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $80,697,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Trading Up 1.7 %

Shares of SRPT opened at $127.10 on Friday. The company’s fifty day simple moving average is $138.26 and its 200-day simple moving average is $132.61. The company has a market cap of $12.01 billion, a P/E ratio of 1,155.45 and a beta of 0.81. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period in the prior year, the company posted ($0.27) EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SRPT. UBS Group boosted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday. Bank of America upped their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Robert W. Baird lifted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Citigroup dropped their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reduced their target price on Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $187.39.

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The disclosure for this sale can be found here. In the last three months, insiders sold 52,801 shares of company stock valued at $8,399,586. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.